[
  {
    "ts": null,
    "headline": "AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)",
    "summary": "Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an analysis of ABBV stock now.",
    "url": "https://finnhub.io/api/news?id=27f13823cd537071c8b0ddc7ecb2cc5e6c311d9c03dd62e33633eeb6d2b40315",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744219792,
      "headline": "AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)",
      "id": 133839000,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150983167/image_2150983167.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an analysis of ABBV stock now.",
      "url": "https://finnhub.io/api/news?id=27f13823cd537071c8b0ddc7ecb2cc5e6c311d9c03dd62e33633eeb6d2b40315"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports",
    "summary": "Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take direct aim at drug imports.",
    "url": "https://finnhub.io/api/news?id=96d7557efd7589ea4007ac05e728527084c4cade1115fc3899b1dfe3df9ca456",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744207584,
      "headline": "Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports",
      "id": 133828250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take direct aim at drug imports.",
      "url": "https://finnhub.io/api/news?id=96d7557efd7589ea4007ac05e728527084c4cade1115fc3899b1dfe3df9ca456"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
    "summary": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer all fell at least 2% Wednesday morning.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK also fell 2% or more in the U.S.",
    "url": "https://finnhub.io/api/news?id=4ad9c1d7fea3deeec7d2b3a280135f38198b941591a33ba2179d1043ce0de99c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744206677,
      "headline": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
      "id": 133828256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer all fell at least 2% Wednesday morning.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK also fell 2% or more in the U.S.",
      "url": "https://finnhub.io/api/news?id=4ad9c1d7fea3deeec7d2b3a280135f38198b941591a33ba2179d1043ce0de99c"
    }
  },
  {
    "ts": null,
    "headline": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
    "summary": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
    "url": "https://finnhub.io/api/news?id=239fef194b45c3e0deed88ea159536c67bcfdddecfa594d190ef5f32a420718c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744199340,
      "headline": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
      "id": 133844748,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Why drug stocks are no longer a safe haven from the stock market’s turmoil",
      "url": "https://finnhub.io/api/news?id=239fef194b45c3e0deed88ea159536c67bcfdddecfa594d190ef5f32a420718c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis",
    "summary": "NORTH CHICAGO - AbbVie today announced that the European Commission granted marketing authorization to RINVOQ for the treatment of giant cell arteritis in adult patients.RINVOQ is the first and...",
    "url": "https://finnhub.io/api/news?id=02a69da3c16fd88a50a27ddb80ac3f254125ccb391e63966ad5cbd016dba315c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744198419,
      "headline": "AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis",
      "id": 133833091,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO - AbbVie today announced that the European Commission granted marketing authorization to RINVOQ for the treatment of giant cell arteritis in adult patients.RINVOQ is the first and...",
      "url": "https://finnhub.io/api/news?id=02a69da3c16fd88a50a27ddb80ac3f254125ccb391e63966ad5cbd016dba315c"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks That Could Set You Up for Life",
    "summary": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.  With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue performing long after: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie went public in 2013, splitting from its former parent company, Abbott Laboratories.",
    "url": "https://finnhub.io/api/news?id=8484a7ed54c85626c0a522e21a812859e2b6ee2a2973cf63e94d62c6728cb33d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744196400,
      "headline": "2 Top Dividend Stocks That Could Set You Up for Life",
      "id": 133828318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.  With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue performing long after: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie went public in 2013, splitting from its former parent company, Abbott Laboratories.",
      "url": "https://finnhub.io/api/news?id=8484a7ed54c85626c0a522e21a812859e2b6ee2a2973cf63e94d62c6728cb33d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s upadacitinib gains EU marketing authorisation for GCA",
    "summary": "The authorisation was based on data from the multicentre Phase III SELECT-GCA trial.",
    "url": "https://finnhub.io/api/news?id=cc49af08620504f09754995e6c4dc2dee94165031a7dcf8c91e04411b1dd826c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744189308,
      "headline": "AbbVie’s upadacitinib gains EU marketing authorisation for GCA",
      "id": 133828320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The authorisation was based on data from the multicentre Phase III SELECT-GCA trial.",
      "url": "https://finnhub.io/api/news?id=cc49af08620504f09754995e6c4dc2dee94165031a7dcf8c91e04411b1dd826c"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Appreciation Strategy Q1 2025 Commentary",
    "summary": "The ClearBridge Appreciation Strategy outperformed the benchmark S&P 500 Index in Q1 2025. Click here to read the full letter.",
    "url": "https://finnhub.io/api/news?id=083f158d4301c89c95f0620eb374801f3c24c5ea5191a271a05948cd419529b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744178100,
      "headline": "ClearBridge Appreciation Strategy Q1 2025 Commentary",
      "id": 133826516,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197707031/image_2197707031.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The ClearBridge Appreciation Strategy outperformed the benchmark S&P 500 Index in Q1 2025. Click here to read the full letter. ",
      "url": "https://finnhub.io/api/news?id=083f158d4301c89c95f0620eb374801f3c24c5ea5191a271a05948cd419529b0"
    }
  }
]